Guest guest Posted June 28, 2008 Report Share Posted June 28, 2008 > [http://images.clinicaloptions.com/img.asp?img=cco/CCO_Header_hep.gif] > > > CME/CE-Certified Treatment Update > New Options for HCV Nonresponders: > Navigating Emerging Data and Best Practices for Treatment-Experienced Patients > > This new Treatment Update provides a comprehensive review of the latest data and best practices on management approaches for patients previously treated unsuccessfully for chronic HCV infection. This program of Virtual Presentations, Interactive Case Challenges, and upcoming teleconferences, during which expert faculty members are available to answer your questions, delivers means for you to synthesize these important data. > > The first part of this Treatment Update is now available online. To access these resources, click here or select an activity below. > > Virtual Presentation > Management of HCV Nonresponders > [http://clinicaloptions.com/upload/global/headshots/jacobson_ira.jpg] > > Join Ira M. son, MD, as he discusses treatment strategies for the optimal management of patients with chronic hepatitis C with previous nonresponse to antiviral therapy. To view this Virtual Presentation, click here. > > > > Downloadable Slideset > The slideset that accompanies this Virtual Presentation is also available for use as a self-study resource or in your own presentations. To download, click here. > [http://clinicaloptions.com/upload/hepatitis/programs/treatment%20experienced%20\ hcv/cco_treatment_experienced_hcv.gif] > > Interactive Case Challenge > Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks > H. Sjogren, MD, MPH, FACP, presents this Interactive Case Challenge in which you make the treatment decisions and compare your answers to those of your colleagues. Dr. Sjogren provides feedback on your answers and explains optimal treatment strategies. To access this Interactive Case Challenge, click here. > > Ask the Experts! > An upcoming teleconference will provide an opportunity to have your questions answered by expert faculty members. To submit your questions on this topic in advance, send an email to hepeditor@.... > > Watch for registration information in your inbox soon! > > This Treatment Update is located online at: > http://clinicaloptions.com/Hepatitis/Treatment%20Updates/Treatment-Experienced%2\ 0HCV.aspx > > > > [http://images.clinicaloptions.com/img.asp?img=/logo/pim.gif] > > [http://images.clinicaloptions.com/img.asp?img=/cco/CCO_hep_logo.jpg] > > Physicians: > Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC. > > Nurses: > Nursing contact hours provided through the cosponsorship of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. > > Release date: June 13, 2008 > Expiration date: June 12, 2009 > > Supported by an educational grant from Three Rivers Pharmaceuticals®. > > [http://images.clinicaloptions.com/img.asp?img=logo/new_logos/threerivers.gif] > > > [http://images.clinicaloptions.com/img.asp?img=/House/Hep/Bookstore_Hep_00g.gif] > > Unsubscribe | Not a member yet? Click here | RSS | Hepatitis Podcasts | Bookstore > > To ensure you receive Clinical Care Options educational materials by email, > please add info@... to your contacts or address book. > > Copyright 2008 Clinical Care Options, LLC. All rights reserved. 1894 Preston White Drive, Suite 110, Reston, VA 20191-5433 _________________________________________________________________ Earn cashback on your purchases with Live Search - the search that pays you back! http://search.live.com/cashback/? & pkw=form=MIJAAF/publ=HMTGL/crea=earncashback Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.